INCY:NGS-Incyte Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 56.86

Change

-0.19 (-0.33)%

Market Cap

USD 20.12B

Volume

3.04M

Analyst Target

USD 106.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.24 (+0.68%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

-1.12 (-0.11%)

USD 110.51B
MRNA Moderna Inc

-2.49 (-1.69%)

USD 57.87B
BNTX BioNTech SE

-1.91 (-1.95%)

USD 24.18B
ARGX argenx NV ADR

+5.84 (+1.53%)

USD 22.94B
ALNY Alnylam Pharmaceuticals Inc

+1.01 (+0.64%)

USD 20.12B
GMAB Genmab AS

-0.36 (-1.34%)

USD 18.17B
BGNE BeiGene Ltd

-1.73 (-1.03%)

USD 17.74B
RPRX Royalty Pharma Plc

N/A

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.31 (-0.37%)

USD 15.32B

ETFs Containing INCY

XDNA:CA iShares Genomics Immunolo.. 3.62 % 0.00 %

N/A

CAD 5.15M
MRND 1.89 % 0.00 %

N/A

N/A
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.06 (+0.00%)

USD 3.30M
GURU Global X Guru Index ETF 0.00 % 0.75 %

-0.28 (0.00%)

USD 0.04B
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

-0.12 (0.00%)

USD 0.14B
UBIO 0.00 % 0.95 %

N/A

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.44% 45% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.44% 45% F 34% F
Trailing 12 Months  
Capital Gain -10.64% 58% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.64% 58% F 37% F
Trailing 5 Years  
Capital Gain -26.35% 66% D+ 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.35% 66% D+ 33% F
Average Annual (5 Year Horizon)  
Capital Gain -6.43% 51% F 31% F
Dividend Return -6.43% 51% F 29% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.77% 98% N/A 80% B-
Risk Adjusted Return -38.37% 36% F 24% F
Market Capitalization 20.12B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 136.80 31% 51%
Price/Book Ratio 2.33 56% 42%
Price / Cash Flow Ratio 26.09 3% 11%
Price/Free Cash Flow Ratio 9.22 3% 28%
Management Effectiveness  
Return on Equity 15.13% 97% 85%
Return on Invested Capital 8.03% 88% 75%
Return on Assets 6.89% 97% 91%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.